A dominant-negative therapy for anthrax.
Leppla
S H
SH
D000818:Animals; D000881:Anthrax / Q000188:drug therapy* / Q000382:microbiology; D022122:Anthrax Vaccines; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000942:Antigens, Bacterial; D001426:Bacterial Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D001427:Bacterial Toxins / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D008958:Models, Molecular; D009154:Mutation; D021122:Protein Subunits
D022122:Anthrax Vaccines; D000900:Anti-Bacterial Agents; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D001427:Bacterial Toxins; D021122:Protein Subunits; C030325:anthrax toxin